Navigation Links
CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting
Date:11/7/2013

less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

CTI is pursuing a broad approach to advancing pacritinib for patients with myelofibrosis by conducting two Phase 3 clinical trials:  one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other will be in patients with low platelet counts, the PERSIST-2 trial, which is expected to begin in the fourth quarter of 2013.  In October 2013, we reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment, or SPA, for the PERSIST-2 pivotal trial.  A SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application, or NDA, submission.  

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials.  CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.

About Cell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable.  CTI is headquartered in Seattle, WA.  For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.  Such statements are s
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ambit Biosciences Announces Third Quarter 2013 Operating Results
2. Spherix Announces the Closing of Private Placement of $2,235,000
3. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
4. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
5. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
6. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
7. AVS announces its major award winners of 2013
8. Metabolix Announces Third Quarter 2013 Financial Results
9. Discovery Labs Announces Completion of $50 Million Public Offering
10. Life Technologies Announces Third Quarter 2013 Results
11. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Eckert ... Accelerator Mass Spectrometry (AMS) services to the pharmaceutical and ... has joined the company in the position of Director ... years of broad and valuable experience in drug metabolism ...
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... State spending on information technology may soon be subject ... costing tens of millions of dollars each, have failed ... and representative Suzanne Jeskewitz, co-chairs of the Joint Audit ... developed or renovated recently are inefficient or non-functional, and ...
... citywide wireless network in Milwaukee, the surrounding communities of ... , ,Waukesha and Wauwatosa are already being pitched by ... the city of Madison. Milwaukee's network is being built ... the deals established so far, the city is essentially ...
... At $2.5 million per 30-second spot, the average 2006 ... TV advertising has never been more affordable for small ... Spot Runner , it's possible to implement a comprehensive ... at a fraction of the normal cost. You can ...
Cached Biology Technology:Local TV advertising - Super Bowl vs. super bargain 2Local TV advertising - Super Bowl vs. super bargain 3Local TV advertising - Super Bowl vs. super bargain 4
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you ... remember your password, site key or the answer to your secret ... Today, Hoyos Labs , a digital infrastructure ... an end to the frustration that comes with usernames, passwords and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... , RENO, Nev. A novel treatment in development at ... common form of muscular dystrophy is advancing towards human trials ... The grant will be used to expand successful research by ... laminin-111 protein therapy prevents the onset of the devastating neuromuscular ...
... the strongest materials on Earth and are used to strengthen ... CNTs have potential uses in everything from medicine to electronics ... study by the University of Missouri and United States Geological ... The researchers urge that care be taken to prevent the ...
... AMES, Iowa Edward Yu took note of the facts ... each year, developments of multidrug-resistant, extensively drug-resistant and now totally ... to tuberculosis. Yu, an Iowa State University and Ames ... the three-part structure that allows E. coli bacteria ...
Cached Biology News:MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 2MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 3Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 2Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 3
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: